The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | The future of AML treatment
Jacqueline Cloos, PhD, of Amsterdam UMC, Amsterdam, The Netherlands, shares her views on the future treatment and management of acute myeloid leukemia (AML), and explains multiple potentially viable methods that need further research. Prof. Cloos talks on the prospects of personalized care becoming an increasingly accessible option due to the various subtypes of AML, highlighting how measurable residual disease (MRD), once standardized and regulated with the help of the AML Working Group, may help to achieve that. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Jacqueline Cloos, PhD, has received institutional research funding from Genentech, BD Biosciences, Novartis, Takeda Pharmaceuticals and Merus; royalties from BD Biosciences and Navigate; and MRD assessments from DC Prime, Helsinn, Janssen, Merus and Novartis.
